A nasal spray may sound easier than an injection, especially if needles make you uncomfortable. That is a reasonable preference to discuss. It should not become an assumption that the two formats deliver the same exposure or results.
Both the exact formulation and the administration route matter. A provider offering both options should explain the evidence and uncertainties for each, along with the practical differences in use, handling, and follow-up.
A preferred delivery format is worth discussing; equivalent effectiveness must not be assumed.
Two different routes, two different sets of instructions
A subcutaneous injection goes beneath the skin, while an intranasal product is applied in the nose. Concentration and container volume alone do not make the formats interchangeable. The amount delivered per application and the way the product is used are also relevant.
Never translate a spray count into an injection amount or reuse instructions from a different preparation. The clinician and pharmacist should supply directions for the exact product dispensed. Ask for clarification if any label detail is ambiguous.
Convenience deserves its own discussion
A person may prefer a nasal format because of needle anxiety or difficulty handling injection supplies. Another may have concerns about the spray device or nasal symptoms. Bring these practical details to the evaluation rather than choosing solely from a product photograph.
Ask how storage works, how the device is used, how long the product remains usable, and how to tell when the container needs replacement. A product promoted as travel-friendly may still have specific handling requirements.
Avoid the stronger-versus-weaker shortcut
Direct administration, needle-free use, and a higher concentration are not clinical outcomes. A claim that one route works better requires research relevant to the actual preparations, doses, and goals being compared. Biology alone cannot settle that question.
Our evidence guide explains why results from an oral precursor or an IV infusion cannot simply be assigned to a nasal product. Ask the clinician which evidence informs the offered route and where uncertainty remains.
Review the actual offer
The current CoreAge Rx review discusses both formats on its linked offer. If you want injections, ensure that selection is carried through to the clinical evaluation and prescription. If you prefer a spray, ask whether the total cost, supply period, and support terms differ.
Changing format may require a new prescription or a revised clinical plan. Confirm the process before purchasing a multi-month supply. A convenient switching message on a website should not replace instructions from the prescriber.
The same careful decision still applies
Compounded products are not FDA-approved. Discuss medical history, medicines, allergies, and the symptom you hope to address. For new or persistent symptoms, ask whether broader evaluation should come first.
Use our consultation checklist to compare answers. Your final choice should account for comfort, practical ability, cost, and evidence limits rather than assume either route is universally best.
Follow the source
References & further reading
- CoreAge Rx — current NAD+ offer
Provider marketing, checked September 19, 2026. Starting offer and terms can change.
- CoreAge Rx — NAD+ Injectable
Provider product page; a different starting price appears here.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.